Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Age-Related Macular Degeneration
Neovascular age-related macular degeneration risk is reduced by hormone therapy
September 20th, 2006
Neovascular age-related macular degeneration (AMD) risk is reduced by hormone therapy. Scientists in the United States conducted a study "to determine the effectiveness of treatment with conjugated equine estrogens (CEE) or with CEE combined with progestin (CEE + P) on AMD. In an ancillary study to the Women's Health Initiative clinical trial of hormone therapy, 4262 women 65 years and older underwent fundus photography for the determination of AMD." "Participants were recruited from April 2000 to June 2002 at 21 clinical sites an average of 5 years after randomization. Participants were randomized to treatment with CEE, CEE + P, or placebo....
Source: Biotech Week (2006-09-20)
|
